MetaCap

Braveheart Bio Inc. (BRVE)

NASDAQ: BRVEHealth CareBiotechnology: Pharmaceutical PreparationsUSD

20.39+1.12 (+5.81%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BRVE stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$6.59
52-week range
16.70 – 32.00
Day range
18.83 – 21.11
Volume / Avg
866.73K / 491.27K
Beta
—
Next earnings
Dec 8, 2026

52-week range

$16.70$32.00

BRVE stock today

Shares of Braveheart Bio (BRVE) finished higher on Nov 20 at $20.39, a gain of 5.81% or $1.12 per share, versus the S&P 500's 3.70% decline. Shares are 36.3% below their 52-week high of $32.00, set on Aug 7, 2026 and 22.1% above the 52-week low of $16.70, in the middle of the past year's range. Braveheart Bio has posted a net loss over the last twelve months (EPS of -$6.59), so its P/E ratio is not meaningful.

The company is scheduled to report Sep/2026 results on Dec 8; analysts expect EPS of -$0.91.

Summary generated from market data by MetaCap's automated system. Methodology

About Braveheart Bio

Company profile

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Travis Murdoch B.S., M.D., M.Sc.
Headquarters
San Francisco, CA
Employees
49
IPO year
2026

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$45.50+123.15%

  • Strong buy 0
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $40.00High $49.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Dec 8, 2026
EPS estimate
$-0.91
Last reported (Sep/2026)
Dec 8, 2026
EPS actual vs est.
$-0.51 vs $-0.91
Surprise
+43.96%

BRVE news

All BRVE news

Braveheart Bio peers

Health Care sector
BRVE peer companies
CompanyPrice% ChgMarket capCompare
RAREUltragenyx Pharmaceutical Inc.16.48-4.30%$1.68Bvs BRVE
AGIOAgios Pharmaceuticals Inc.27.60-4.03%$1.65Bvs BRVE
KRSAKorsana Biosciences Inc.37.56+5.95%$1.71Bvs BRVE
SDGRSchrodinger Inc.22.93-12.95%$1.72Bvs BRVE
ZBIOZenas BioPharma Inc.23.85-4.75%$1.62Bvs BRVE
TRAXFirst Tracks Biotherapeutics Inc.41.64-6.34%$1.75Bvs BRVE
STOKStoke Therapeutics Inc.26.81-0.45%$1.75Bvs BRVE
ETONEton Pharmaceuticals Inc.60.85-0.83%$1.76Bvs BRVE

Indexes, lists and sector

Braveheart Bio stock FAQ

What is Braveheart Bio's stock price today?

BRVE last traded at $20.39 as of Nov 20, 4:00 PM EST, up 5.81% on the day. Prices are delayed at least 15 minutes.

When is Braveheart Bio's next earnings date?

Braveheart Bio is expected to report earnings on Tuesday, December 8, 2026. Analysts expect EPS of $-0.91.

Who is Braveheart Bio's CEO?

Dr. Travis Murdoch B.S., M.D., M.Sc. is the chief executive officer of Braveheart Bio Inc., which has about 49 employees.

What is the BRVE 52-week high?

The 52-week high for BRVE is $32.00 and the 52-week low is $16.70. The stock is currently 36.3% below its high.

Compare BRVE